CLRB— Cellectar Biosciences, Inc.

MaterialsBiotechnology$21M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$11.5M-56.0%	$26.1M-4.1%	$27.3M+41.9%	$19.2M
General and administrative	$11.5M-55.2%	$25.6M+119.3%	$11.7M+21.9%	$9.6M
Total operating expenses	$23.0M-55.6%	$51.8M+32.9%	$39.0M+35.2%	$28.8M
LOSS FROM OPERATIONS	-$23.0M+55.6%	-$51.8M-32.9%	-$39.0M-35.2%	-$28.8M
Warrant issuance expense	-$7.7M	—	-$470K	—
Gain on valuation of warrants	$754K-94.5%	$13.8M+464.3%	-$3.8M	—
Interest income	$435K-64.1%	$1.2M+212.8%	$387K+153.8%	$153K
Total other income (expense), net	$1.2M-83.6%	$7.3M+287.7%	-$3.9M-2637.4%	$153K
LOSS BEFORE INCOME TAXES	-$21.8M+51.0%	-$44.5M-3.9%	-$42.8M-49.4%	-$28.7M
INCOME TAX PROVISION (BENEFIT)	$66K	—	-$60K+0.0%	-$60K
NET LOSS	-$21.8M+51.1%	-$44.6M-4.2%	-$42.8M-49.5%	-$28.6M
NET LOSS PER SHARE - BASIC (In dollars per share)	-$8.35+77.1%	-$36.52-943.4%	-$3.50+13.6%	-$4.05
NET LOSS PER SHARE - DILUTED (In dollars per share)	-$8.35+80.1%	-$41.89-1096.9%	-$3.50+13.6%	-$4.05
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares)	2.6M+113.7%	1.2M-90.0%	12.2M+73.2%	7.1M
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares)	2.6M+110.7%	1.2M-89.9%	12.2M+73.2%	7.1M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.